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longed activated clotting time (ACT) with aprotinin 
depends on the type of activator used for measure- 
ment. Blood Coagul Fibrinolysis 1993;4:4l-5. 
Commentary 
Coagulation abnormalities and bleeding commonly oc- 
cur after profoundly hypothermic perfusion and circula- 
tory arrest. This was an obvious area to test the potential 
benefits of aprotinin, and adverse clinical experience was 
reported early, when there was little guidance on intraop- 
erative anticoagulant policy, a' 2 The article from Goldstein 
and colleagues presents a contrary view of the hazards of 
aprotinin in profound hypothermia nd claims benefits. 
The authors confirm an increased incidence of renal 
failure in aprotinin-treated patients but do not report 
multisystem failure from widespread platelet fibrin 
thrombi in the microvasculature. With the exception of 
anaphylaxis, most adverse ffects of aprotinin have been 
attributed to deficiencies in the anticoagulant regimen. In 
reality, improved guidelines emerged only after reports of 
catastrophic events when early protocols were followed) 
The article of Goldstein and colleagues uggests yet 
another modification in anticoagulant policy, with ACT 
maintained at longer than 1000 seconds for patients 
undergoing hypothermic circulatory arrest. 
When aprotinin was found to artifactually prolong 
celite ACT, the setting for inadequate anticoagulation 
became apparent. This situation should have been clearly 
defined before release of the drug in Europe and clinical 
trials in the United States. ACT is also inversely related to 
temperature. Although this effect is expressed equally in 
aprotinin-treated and control patients, it reduces the 
likelihood of reaching an ACT low enough to prompt 
further heparin administration. In the hypothermic pa- 
tients described independently by Westaby and cowork- 
ers ! and Sundt and associates, 2 artifactual prolongation of 
ACT caused aprotinin-treated patients to receive less 
heparin than did control patients. With the benefit of this 
information, Goldstein a d colleagues maintained celite 
ACT at longer than 750 seconds, or longer than 500 
seconds with kaolin provocation, which is unaffected by 
aprotinin. In fact, patients treated with aprotinin received 
considerably more heparin and had ACTs longer than 
1000 seconds, versus around 700 seconds for control 
patients. These are substantial differences between treat- 
ment and historical control patients, and the avoidance of 
disseminated intravascular coagulopathy supports the wis- 
dom of this approach. Another difference between the 
Columbia and Oxford patients was duration of CPB. 
Oxford patients were maintained with a celite ACT longer 
than 700 seconds but had much shorter duration f CPB 
(<100 minutes versus >200 minutes). Differences in the 
ability of platelets to aggregate may" have played a role in 
the Oxford patients with type I dissection who had dis- 
seminated intravascnlar coagulation during circulatory 
arrest. Inhibition by aprotinin of the protein C and 
kallikrein-kinin systems and of % antiplasmin consump- 
tion also predispose the patient oward a prothrombotic 
state during circulatory arrest. 1' 3 
Hypothermia alone causes altered platelet morphology, 
with an increase in mean platelet volume, decreased 
enzyme function, altered arachadonic acid metabolism, 
and platelet sequestration i  the hepatic sinusoids. 4 This 
alteration leads to thrombocytopenia. Decreased ability to 
aggregate arises through reduced thromboxane release 
and the influence of plasmin-related degradation of gly- 
coprotein Ib receptors. In normal circumstances (without 
aprotinin), thorough rewarming reverses impaired aggre- 
gation and depressed enzyme kinetics and is probably the 
single most important factor in the prevention of postop- 
erative bleeding. 5" 6 The influence of hypothermia on the 
clotting cascades is also complex. Hibernating amphibians 
have lower levels of clotting factors in the cold, which 
represents an adaptive response to prevent thrombosis 
during sluggish flow. Primates have lost this facility, apart 
from the kinetic slowing of enzyme activity during cool- 
ing. 7 Consequently, the balance between thrombosis and 
flbrinolysis may be easily disturbed during hypothermic 
low-flow states and circulatory arrest. Cold-induced hy- 
percoagulability may have contributed to widespread mi- 
crovascular coagulopathy in the patients with thoracoab- 
dominal aneurysms in the series of Sundt and coworkers) 
Bacterial trauslocation through ischemic gut can result in 
endotoxin release. 8 This in turn stimulates the monocytes 
to produce thromboplastin and activate the extrinsic 
clotting pathway-. The combination of cold-induced hyper- 
coagulability with endotoxemia results in disseminated 
intravascular coagulation. 
Does the study of Goldstein and colleagues really 
demonstrate benefit from aprotinin treatment? As with 
previous studies, there are methodoiogic weaknesses, 
particularly lack of randomization and the potential for 
bias. The authors admit that a randomized study design 
was not acceptable to the surgeons. This could be 
interpreted as bias in favor of aprotinin. In addition, the 
control group was not concurrent with the study group 
but overlapped it in time. Because the safety of apro- 
tinin had been questioned, was the drug withheld from 
individuals considered to be at high risk for thrombo- 
embolic or nephrotoxic complications? There was no 
difference in intraoperative transfusion requirements 
for erythrocytes, platelets, fresh-frozen plasma, or cryo- 
precipitate. The authors did not state their threshold 
for blood transfusion, but there was no difference in 
chest tube drainage between the groups. Why then did 
patients with aprotinin require f wer blood products in
the postoperative period? 
In summary, this article continues the debate around 
the safety of aprotinin and suggests that prolongation of 
ACT longer than 1000 seconds may prevent he adverse 
effects described by Westaby and coworkers ~and Sundt 
and associates. 2 Benefits from aprotinin in profound 
hypothermia and circulatory arrest are yet to be proved. 
and I agree with the authors that  prospective random- 
ized trial is necessary. Meanwhile, my group uses aproti- 
nin during the rewarming phase after circulatory arrest or 
by topical application or intravenous infusion at the end of 
the procedure if bleeding is a problem. 
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